.png)
New York, NY. Jan 22, 2026 –
Today, Salvo Health announced a $8.5M Series A funding round led by ManchesterStory, City Light Capital, and Threshold Ventures, with participation from new investors including The Artemis Fund, Contour Venture Partners, and others.
Salvo Health is emerging as the leader in helping gastrointestinal (GI) providers across the U.S. adopt a hybrid, AI-enhanced care model, offering brick & mortar clinics an easy-to-implement continuous care platform that saves time, increases revenue, and improves patient outcomes.
Salvo ended 2025 having grown patients and revenue by 800% YoY, and enterprise agreements with GI doctors by more than 1,000%.
Salvo has signed agreements with 801 GIs, representing 16% of all independent GIs in the U.S., to deploy wraparound care for their clinic patients. Enterprise customers include three of the four largest GI practices in the country, together seeing over 1.1 million GI patients a year across ten states.
Other new equity investors with this Series A funding include Owl Capital and Impact X Capital Partners. Both were previously investors from Salvo’s separate $4.7M Convertible Note raised in 2025. In addition, existing investors Human Ventures, Torch Capital, Felicis Ventures, and Alumni Ventures all participated in the latest round.
“We invested in Salvo to expand access to ‘whole person’ care to communities across the country where there can be a shortage of GI providers and obstacles to finding world-class multidisciplinary, team-based care,” commented Matt Kinley, Founding Partner of venture capital firm ManchesterStory.
“Salvo is allowing community GI practices to build ‘Center of Excellence’ care for the 100 million Americans who suffer from chronic GI conditions such as IBD, IBS, GERD, celiac, and gastroparesis, as well as metabolic conditions such as MASLD and general obesity.”
“Salvo Health is winning because they chose to empower GI providers, not replace them,” said Diana Murakhovskaya, General Partner at The Artemis Fund. “With deep enterprise adoption, accelerating deployments, and a clear path to profitability, Salvo has emerged as the glue for modern multi-disciplinary GI care.
We love that Salvo, like other leaders in the care economy, is treating AI as an accelerant, not the product. This round is about scaling a proven platform across one of healthcare’s largest and most underserved specialties.”
“We see gut health as a missing ingredient in women’s health and mental health progress in this country,” said Katie Reiner Peykar, Partner at Torch Capital. “83% of Salvo patients are women, reflecting the disproportionate impact of chronic GI burdens on women, and the legacy of stigma and gaslighting—especially around IBS and obesity care. Salvo won a Blue Ribbon at the American College of Gastroenterology (ACG) annual meeting for its research, showing not only symptom improvement, but also over 54% of patients showing mental health gains.”
“We believe the future lies in enabling GI providers to evolve into an elegant mix of human and agentic AI care,” added Jennifer Fonstad, Managing Partner at Owl Capital. “Salvo is giving provider organizations a glide path to incorporating AI as well as a graceful path from today’s fee-for-service system to a value-based care future that is still in early innings.”
“The key with Salvo is patient-centered care,” said Eric Collins, Co-Founder and General Partner of Impact X Capital Partners, a UK-based venture capital firm. “It’s critical to expand access to food as medicine and behavioral health to improve outcomes and lower long-term health care costs. Salvo does exactly that and has shown 76% of patients report improved symptoms, with five accepted abstracts on outcomes, and a 79% drop in GI-related ER utilization for its patients. We can have better care at lower costs with innovation, in the U.S., and ultimately in the U.K. and Europe as well.”
“We see trusted community GI providers as an under-leveraged channel to deliver comprehensive follow-on care,” noted Josh Cohen, Managing Partner at City Light Capital. “That is not just for GI conditions but also for metabolic syndrome and obesity, conditions that affect 100 million Americans for which Salvo has proven outcomes.”
This round brings Salvo’s cumulative equity raised to $21.6 million on its capital table. Salvo’s founding leadership team—including CEO Jeffrey Glueck, COO Marin Rothenberg, and CMO Dr. Erin Hendriks—along with executive team members Amanda Sussex (Head of Partnerships), Luke Rohde (Head of Engineering), and Mary Moreno (Head of Product), plans to use proceeds raised to expand Salvo’s engineering team with an AI-led roadmap and to increase national hiring of registered dietitians, behavioral health professionals, and nurses to meet rising patient demand.
Press Contact:
Info@SalvoHealth.com
.png)
.png)
.png)
.png)